Search in:

Expert Opinion on Drug Safety Volume 7, 2008 - Issue 4

Submit an article Journal homepage

183

Views

CrossRef citations to date

Altmetric

Reviews

The cardiovascular safety of rosiglitazone

Ramzi A Ajjan University of Leeds, Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics Health and Therapeutics, Clarendon Way, Leeds LS2 9JT, UK +44 113 343 7721; +44 113 343 7738; [email protected]

Peter J Grant University of Leeds, Division of Cardiovascular and Diabetes Research, Leeds Institute of Genetics Health and Therapeutics, Clarendon Way, Leeds LS2 9JT, UK +44 113 343 7721; +44 113 343 7738; [email protected]

Pages 367-376 | Published online: 10 Jul 2008

Cite this article
https://doi.org/10.1517/14740338.7.4.367

Full Article
Figures & data
References
Citations
Metrics
Reprints & Permissions

Bibliography

Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351:1106-18
PubMed Web of Science ®Google Scholar
Bailey CJ. Treating insulin resistance in Type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005;7:675-91
PubMed Web of Science ®Google Scholar
Verges B. Diabetic dyslipidaemia: insights for optimizing patient management. Curr Med Res Opin 2005;21(Suppl 1):S29-40
PubMed Web of Science ®Google Scholar
van Wijk JP, de Koning EJ, Martens EP, Rabelink TJ. Thiazolidinediones and blood lipids in Type 2 diabetes. Arterioscler Thromb Vasc Biol 2003;23:1744-9
PubMed Web of Science ®Google Scholar
Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-104
PubMed Web of Science ®Google Scholar
Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert Opin Pharmacother 2008;9:343-9
PubMed Web of Science ®Google Scholar
Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 2005;28:1547-54
PubMed Web of Science ®Google Scholar
Khan M, Berhanu P, Perez A. Effects of pioglitazone in combination with stable statin therapy on lipid levels in subjects with Type 2 diabetes and dyslipidemia after treatment conversion from rosiglitazone: results from an open label study. Diab Vasc Dis Res 2006;3:39-44
PubMedGoogle Scholar
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with Type 2 diabetes in the PROactive Study (Prospective Pioglitazone Clinical Trial in Macrovascular Events): a randomised controlled trial. Lancet 2005;366:1279-89
PubMed Web of Science ®Google Scholar
Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with Type 2 diabetes and dyslipidemia. Diabetes Care 2007;30:2458-64
PubMed Web of Science ®Google Scholar
Raji A, Seely EW, Bekins SA, et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients. Diabetes Care 2003;26:172-8
PubMed Web of Science ®Google Scholar
Fullert S, Schneider F, Haak E, et al. Effects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. J Clin Endocrinol Metab 2002;87:5503-6
PubMed Web of Science ®Google Scholar
St John SM, Rendell M, Dandona P, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with Type 2 diabetes. Diabetes Care 2002;25:2058-64
PubMed Web of Science ®Google Scholar
Hetzel J, Balletshofer B, Rittig K, et al. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers. Arterioscler Thromb Vasc Biol 2005;25:1804-9
PubMed Web of Science ®Google Scholar
Harte A, McTernan P, Chetty R, et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 2005;111:1954-61
PubMed Web of Science ®Google Scholar
Bakris G, Viberti G, Weston WM, et al. Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 2003;17:7-12
PubMed Web of Science ®Google Scholar
Nakamura T, Ushiyama C, Shimada N, et al. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients. J Diabetes Complications 2000;14:250-4
PubMed Web of Science ®Google Scholar
Kelly AS, Bank AJ. The cardiovascular effects of the thiazolidinediones: a review of the clinical data. J Diabetes Complications 2007;21:326-34
PubMed Web of Science ®Google Scholar
Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with Type 2 diabetes mellitus. Circulation 2002;106:679-84
PubMed Web of Science ®Google Scholar
Li D, Chen K, Sinha N, et al. The effects of PPAR-gamma ligand pioglitazone on platelet aggregation and arterial thrombus formation. Cardiovasc Res 2005;65:907-12
PubMed Web of Science ®Google Scholar
Calnek DS, Mazzella L, Roser S, et al. Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003;23:52-7
PubMed Web of Science ®Google Scholar
Zirlik A, Leugers A, Lohrmann J, et al. Direct attenuation of plasminogen activator inhibitor type-1 expression in human adipose tissue by thiazolidinediones. Thromb Haemost 2004;91:674-82
PubMed Web of Science ®Google Scholar
Derosa G, Cicero AF, Gaddi A, et al. A comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in Type 2 diabetic patients with the metabolic syndrome. Diabetes Res Clin Pract 2005;69:5-13
PubMed Web of Science ®Google Scholar
Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-7
PubMed Web of Science ®Google Scholar
Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with Type 2 diabetes mellitus: results from a controlled randomized study. Circulation 2005;111:2525-31
PubMed Web of Science ®Google Scholar
Mazzone T, Meyer PM, Feinstein SB, et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in Type 2 diabetes: a randomized trial. JAMA 2006;296:2572-81
PubMed Web of Science ®Google Scholar
Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 2004;24:930-4
PubMed Web of Science ®Google Scholar
Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with Type 2 diabetes. Diabetes Care 2004;27:2654-60
PubMed Web of Science ®Google Scholar
Nishio K, Sakurai M, Kusuyama T, et al. A randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with Type 2 diabetes. Diabetes Care 2006;29:101-6
PubMed Web of Science ®Google Scholar
Marx N, Wohrle J, Nusser T, et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005;112:2792-8
PubMed Web of Science ®Google Scholar
Riche DM, Valderrama R, Henyan NN. Thiazolidinediones and risk of repeat target vessel revascularization following percutaneous coronary intervention: a meta-analysis. Diabetes Care 2007;30:384-8
PubMed Web of Science ®Google Scholar
Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002;39:10-5
PubMed Web of Science ®Google Scholar
Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in Type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003;26:2493-9
PubMed Web of Science ®Google Scholar
Shargorodsky M, Wainstein J, Gavish D, et al. Treatment with rosiglitazone reduces hyperinsulinemia and improves arterial elasticity in patients with Type 2 diabetes mellitus. Am J Hypertens 2003;16:617-22
PubMed Web of Science ®Google Scholar
PROactive: Prospective Pioglitazone Clinical Trial in Macrovascular Events. Proactive-results.com2006
Google Scholar
Wilcox R, Bousser MG, Betteridge DJ, et al. Effects of pioglitazone in patients with Type 2 diabetes with or without previous stroke: results from PROactive (Prospective Pioglitazone Clinical Trial in Macrovascular Events 04). Stroke 2007;38:865-73
PubMed Web of Science ®Google Scholar
Ceriello A. PROactive study: (r)evolution in the therapy of diabetes? Diabet Med 2005;22:1463-4
PubMed Web of Science ®Google Scholar
Gaede P, Parving HH, Pedersen O. PROactive study. Lancet 2006;367:23-4
PubMedGoogle Scholar
Holman RR, Retnakaran R, Farmer A, Stevens R. PROactive study. Lancet 2006;367:25-6
PubMed Web of Science ®Google Scholar
Yki-Jarvinen H. The PROactive study: some answers, many questions. Lancet 2005;366:1241-2
PubMed Web of Science ®Google Scholar
Fonseca V, Jawa A, Asnani S. Commentary: the PROactive study: the glass is half full. J Clin Endocrinol Metab 2006;91:25-7
PubMed Web of Science ®Google Scholar
Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008;29:12-20
PubMed Web of Science ®Google Scholar
Masoudi FA, Inzucchi SE, Wang Y, et al. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 2005;111:583-90
PubMed Web of Science ®Google Scholar
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005;48:1726-35
PubMed Web of Science ®Google Scholar
Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med 2007;357:28-38
PubMed Web of Science ®Google Scholar
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43
PubMed Web of Science ®Google Scholar
Krall RL. Cardiovascular safety of rosiglitazone. Lancet 2007;369:1995-6
PubMed Web of Science ®Google Scholar
Dahabreh IJ. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone. Clin Trials 2008;5:116-20
PubMed Web of Science ®Google Scholar
Lipscombe LL, Gomes T, Levesque LE, et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 2007;298:2634-43
PubMed Web of Science ®Google Scholar
Inzucchi SE, Masoudi FA, Wang Y, et al. Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. Diabetes Care 2005;28:1680-9
PubMed Web of Science ®Google Scholar
McAfee AT, Koro C, Landon J, et al. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf 2007;16:711-25
PubMed Web of Science ®Google Scholar
Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71
PubMed Web of Science ®Google Scholar
Bloomgarden ZT. The Avandia debate. Diabetes Care 2007;30:2401-8
PubMed Web of Science ®Google Scholar
Shuster JJ, Jones LS, Salmon DA. Fixed vs random effects meta-analysis in rare event studies: the rosiglitazone link with myocardial infarction and cardiac death. Stat Med 2007;26:4375-85
PubMed Web of Science ®Google Scholar
Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578-81
PubMed Web of Science ®Google Scholar
McGuire DK. Rosiglitazone and cardiovascular disease: an epidemiologist's perspective. Diab Vasc Dis Res 2007;4:77-9
PubMedGoogle Scholar
Lincoff AM, Wolski K, Nicholls SJ, Nissen SE. Pioglitazone and risk of cardiovascular events in patients with Type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007;298:1180-8
PubMed Web of Science ®Google Scholar
Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007;298:1189-95
PubMed Web of Science ®Google Scholar
Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and Type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129-36
PubMed Web of Science ®Google Scholar
Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of Type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol 2005;46:821-6
PubMed Web of Science ®Google Scholar
Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006;355:1551-62
PubMed Web of Science ®Google Scholar
The action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in Type 2 diabetes. N Engl J Med 2008;358:2545-59
Google Scholar
Sakamoto J, Kimura H, Moriyama S, et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000;278:704-11
PubMed Web of Science ®Google Scholar
Boden G, Homko C, Mozzoli M, et al. Combined use of rosiglitazone and fenofibrate in patients with Type 2 diabetes: prevention of fluid retention. Diabetes 2007;56:248-55
PubMed Web of Science ®Google Scholar
Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with Type 2 diabetes mellitus. JAMA 2005;294:2581-6
PubMed Web of Science ®Google Scholar
Gazzaruso C, Solerte SB, De Amici E, et al. Association of the metabolic syndrome and insulin resistance with silent myocardial ischemia in patients with Type 2 diabetes mellitus. Am J Cardiol 2006;97:236-9
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Share icon
Back to Top

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

The cardiovascular safety of rosiglitazone

Bibliography

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The cardiovascular safety of rosiglitazone

Bibliography

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date